NACDS Statement on FDA’s Recommendation to Reschedule Hydrocodone

Published Online: Friday, October 25, 2013
Follow Pharmacy_Times:
PRESS RELEASE

Arlington, Va. - NACDS issued the following statement on October 24 regarding news that the Food and Drug Administration (FDA) is recommending the rescheduling of combination hydrocodone medications from Schedule III to Schedule II:

“Pharmacies have a zero tolerance for prescription drug abuse and a 100-percent commitment to patient care. This proposal is not the best avenue to address abuse, and would negatively impact access to needed medications for those who suffer from chronic pain. In the interest of patient care, we have worked with patient advocacy groups in opposition to this recommendation as we support and advance workable solutions.”

For more information, please see a recent column by NACDS President and CEO Steven C. Anderson, IOM, CAE, titled “Addressing Prescription Drug Abuse and Access Issues – Every Day.”
Related Articles
A former pharmacy technician thought the prescription pill records she was finagling were better shred than read.
A Maryland pharmacist has been charged with the theft of more than 7300 tablets of hydrocodone, a painkiller found in Vicodin and Lortab.
The FDA today approved hydrocodone bitartrate, an extended-release opioid analgesic for treating severe pain that requires daily long-term opioid treatment and for which other treatment options are inadequate.
Latest Issues
$auto_registration$